

# Andrew J Muir

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2493401/publications.pdf>

Version: 2024-02-01

101  
papers

6,269  
citations

201674

27  
h-index

66911

78  
g-index

102  
all docs

102  
docs citations

102  
times ranked

6359  
citing authors

#	ARTICLE	IF	CITATIONS
1	Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection. <i>New England Journal of Medicine</i> , 2011, 364, 2405-2416.	27.0	2,278
2	Peginterferon Alfa-2b and Ribavirin for the Treatment of Chronic Hepatitis C in Blacks and Non-Hispanic Whites. <i>New England Journal of Medicine</i> , 2004, 350, 2265-2271.	27.0	537
3	Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation. <i>Gastroenterology</i> , 2015, 148, 108-117.	1.3	317
4	Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1 without cirrhosis. <i>Journal of Hepatology</i> , 2017, 67, 263-271.	3.7	261
5	Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2018, 155, 1140-1153.	1.3	253
6	The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. <i>Hepatology</i> , 2019, 70, 1913-1927.	7.3	226
7	Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. <i>Hepatology</i> , 2010, 52, 822-832.	7.3	212
8	American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases. <i>Gastroenterology</i> , 2017, 152, 1544-1577.	1.3	208
9	The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2019, 70, 788-801.	7.3	180
10	Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. <i>Journal of Hepatology</i> , 2019, 70, 483-493.	3.7	124
11	Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. <i>Hepatology</i> , 2019, 69, 684-698.	7.3	121
12	A Descriptive Evaluation of Eligibility for Therapy Among Veterans With Chronic Hepatitis C Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2002, 34, 268-271.	2.2	106
13	A Survey of Current Liver Biopsy Practice Patterns. <i>Journal of Clinical Gastroenterology</i> , 2002, 35, 86-88.	2.2	94
14	Reducing medication regimen complexity. <i>Journal of General Internal Medicine</i> , 2001, 16, 77-82.	2.6	92
15	Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGET. <i>Journal of Hepatology</i> , 2015, 62, 286-293.	3.7	86
16	Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1728.	7.4	85
17	Racial and Socioeconomic Disparities in Utilization of Telehealth in Patients with Liver Disease During COVID-19. <i>Digestive Diseases and Sciences</i> , 2022, 67, 93-99.	2.3	78
18	The Rapid Evolution of Treatment Strategies for Hepatitis C. <i>American Journal of Gastroenterology</i> , 2014, 109, 628-635.	0.4	71

#	ARTICLE	IF	CITATIONS
19	Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. <i>Hepatology</i> , 2011, 54, 1538-1546.	7.3	49
20	Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2022, 75, 1235-1246.	7.3	45
21	Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2166-2172.	4.4	40
22	Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. <i>Journal of Hepatology</i> , 2014, 60, 748-756.	3.7	37
23	Understanding the Complexities of Cirrhosis. <i>Clinical Therapeutics</i> , 2015, 37, 1822-1836.	2.5	37
24	Role of patient factors, preferences, and distrust in health care and access to liver transplantation and organ donation. <i>Liver Transplantation</i> , 2016, 22, 895-905.	2.4	33
25	Natural history of liver imaging reporting and data system category 4 nodules in MRI. <i>Abdominal Radiology</i> , 2016, 41, 1758-1766.	2.1	33
26	A Systematic Review of Race and Ethnicity in Hepatitis C Clinical Trial Enrollment. <i>Journal of the National Medical Association</i> , 2016, 108, 24-29.	0.8	30
27	Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. <i>Journal of Hepatology</i> , 2020, 72, 431-440.	3.7	30
28	An Integrated Alcohol Abuse and Medical Treatment Model for Patients with Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1083-1091.	2.3	27
29	Liver imaging reporting and data system category 4 observations in MRI: Risk factors predicting upgrade to category 5. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 783-792.	3.4	27
30	Randomized trial of an uncertainty self-management telephone intervention for patients awaiting liver transplant. <i>Patient Education and Counseling</i> , 2017, 100, 509-517.	2.2	27
31	Efforts at the Frontlines: Implementing a Hepatitis C Testing and Linkage-to-Care Program at the Local Public Health Level. <i>Public Health Reports</i> , 2016, 131, 57-64.	2.5	26
32	Outcomes of liver retransplantation in patients with primary sclerosing cholangitis. <i>Liver Transplantation</i> , 2017, 23, 769-780.	2.4	26
33	Significant Morbidity and Mortality Among Hospitalized End-Stage Liver Disease Patients in Medicare. <i>Journal of Pain and Symptom Management</i> , 2016, 52, 412-419.e1.	1.2	25
34	Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1248-1257.	4.4	25
35	A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C Infection. <i>Hepatology</i> , 2020, 71, 1894-1909.	7.3	24
36	Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PRO. <i>Hepatology</i> , 2018, 68, 155-165.	7.3	22

#	ARTICLE	IF	CITATIONS
37	The use of complementary and alternative medicine by patients with chronic hepatitis C. <i>Complementary Therapies in Clinical Practice</i> , 2010, 16, 124-131.	1.7	20
38	IL28B in the Era of Direct-acting Antivirals for Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 222-227.	2.2	18
39	Use of Skeletal Muscle Index as a Predictor of Waitlist Mortality in Patients With End-stage Liver Disease. <i>Liver Transplantation</i> , 2020, 26, 1090-1099.	2.4	18
40	Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2544-2553.e6.	4.4	18
41	Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 468-476.e11.	4.4	16
42	Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features. <i>European Radiology</i> , 2021, 31, 3638-3648.	4.5	15
43	Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. <i>Transplant International</i> , 2017, 30, 196-208.	1.6	14
44	A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2021, 73, 1105-1116.	7.3	14
45	Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 314-327.	2.5	13
46	Telaprevir for the treatment of chronic hepatitis C infection. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 1105-1114.	4.4	12
47	Transplant Outcomes in Older Patients With Nonalcoholic Steatohepatitis Compared to Alcohol-related Liver Disease and Hepatitis C. <i>Transplantation</i> , 2020, 104, e164-e173.	1.0	11
48	Evaluation of New-Onset Ascites. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 340.	7.4	10
49	Differences in Phenotypes and Liver Transplantation Outcomes by Age Group in Patients with Primary Sclerosing Cholangitis. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3200-3209.	2.3	10
50	Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 438-446.	4.4	10
51	Trends in statin utilisation in US adults with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1481-1489.	3.7	10
52	Diagnosing Liver Fibrosis and Cirrhosis: Serum, Imaging, or Tissue?. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 16-18.	4.4	9
53	Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis. <i>JHEP Reports</i> , 2020, 2, 100060.	4.9	9
54	Addressing Hepatitis C in the American Incarcerated Population: Strategies for Nationwide Elimination. <i>Current HIV/AIDS Reports</i> , 2020, 17, 18-25.	3.1	9

#	ARTICLE	IF	CITATIONS
55	Patterns of Healthcare Utilization Among Veterans Infected With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) and Coinfected With HIV/HCV: Unique Burdens of Disease. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw173.	0.9	8
56	Clinical Encounters and Treatment Initiation for Chronic Hepatitis C Patients: Applications of Adaptive Leadership Framework for Chronic Illness. <i>SAGE Open</i> , 2019, 9, 215824401882446.	1.7	8
57	Proton pump inhibitor use is associated with increased rates of post-TIPS hepatic encephalopathy: Replication in an independent patient cohort. <i>Clinical Imaging</i> , 2021, 77, 187-192.	1.5	8
58	Development of a Measure of Hepatitis C-alcohol Knowledge. <i>Journal of Alcohol and Drug Education</i> , 2014, 58, 7-18.	2.0	8
59	Surgical Clearance for the Patient with Chronic Liver Disease. <i>Clinics in Liver Disease</i> , 2012, 16, 421-433.	2.1	7
60	The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2018, 72, 73-85.	1.8	7
61	A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. <i>Hepatology</i> , 2021, 74, 2952-2964.	7.3	7
62	A retrospective longitudinal study and comprehensive review of adult patients with glycogen storage disease type III. <i>Molecular Genetics and Metabolism Reports</i> , 2021, 29, 100821.	1.1	7
63	The impact of human leukocyte antigen donor and recipient serotyping and matching on liver transplant graft failure in primary sclerosing cholangitis, autoimmune hepatitis, and primary biliary cholangitis. <i>Clinical Transplantation</i> , 2018, 32, e13388.	1.6	6
64	Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Canâ€™t Do?. <i>Journal of Infectious Diseases</i> , 2020, 222, S794-S801.	4.0	6
65	Nonâ€™irrotic thrombocytopenic patients with hepatitis <scp>C</scp> virus: Characteristics and outcome of antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1301-1308.	2.8	5
66	Hepatocellular Carcinoma Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 19-20.	4.4	5
67	AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2022, 162, 937-951.	1.3	5
68	Access to technology to support telehealth in areas without specialty care for liver disease. <i>Hepatology</i> , 2023, 77, 176-185.	7.3	5
69	An examination of factors predicting prioritization for liver transplantation. <i>Liver Transplantation</i> , 2002, 8, 957-961.	2.4	4
70	Prediction of Treatment Week Eight Response & Sustained Virologic Response in Patients Treated with Boceprevir Plus Peginterferon Alfa and Ribavirin. <i>PLoS ONE</i> , 2014, 9, e103370.	2.5	4
71	The clinical and economic burden of patients with chronic liver disease and thrombocytopaenia receiving platelet transfusions during planned invasive procedures. <i>GastroHep</i> , 2019, 1, 236-248.	0.6	4
72	Impact of Malnutrition on Outcomes in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Insertion. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3332-3340.	2.3	4

#	ARTICLE	IF	CITATIONS
73	Socioeconomic Status Is Associated with the Risk of Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 950-960.e1.	0.5	4
74	Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 451-456.	1.8	3
75	Great Expectations: Can Magnetic Resonance Elastography Accelerate Progress in Primary Sclerosing Cholangitis Research?. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1436-1438.	4.4	3
76	Reduced Alcohol Use Is Sustained in Patients Provided Alcohol-Related Counseling During Direct-Acting Antiviral Therapy for Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2956-2963.	2.3	3
77	A Big Step Forward in Hepatitis C Screening. <i>Clinical Liver Disease</i> , 2020, 15, 149-152.	2.1	3
78	Racial disparities in transjugular intrahepatic portosystemic shunt procedure outcomes. <i>BMJ Open Gastroenterology</i> , 2022, 9, e000747.	2.7	3
79	The impact of race and ethnicity on the treatment of hepatitis C disease. <i>Current Hepatitis Reports</i> , 2006, 5, 79-85.	0.3	2
80	Why do patients with chronic hepatitis C drink alcohol? An examination of pain, depression and drinking motives. <i>Journal of Viral Hepatitis</i> , 2021, 28, 699-709.	2.0	2
81	Patient-Predicted Outcomes Are Associated with Quality of Life in Patients with Primary Sclerosing Cholangitis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5483-5492.	2.3	2
82	HCV genotype 2 and 3 infections: what is the optimal duration for peginterferon $\alpha$ -2b and ribavirin therapy?. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2005, 2, 568-569.	1.7	1
83	Treatment of HCV in Renal Disease: Subtle Management Considerations in the Era of Direct-Acting Antivirals. <i>Current Hepatology Reports</i> , 2016, 15, 285-290.	0.9	1
84	Integrating daclatasvir into hepatitis c therapy. <i>Clinical Liver Disease</i> , 2016, 7, 1-4.	2.1	1
85	Hepatitis C Behind and Beyond Bars. <i>North Carolina Medical Journal</i> , 2019, 80, 352-355.	0.2	1
86	N-Acetylcysteine in the Management of Acute Liver Failure From Sickle Cell Hepatic Crisis. <i>ACG Case Reports Journal</i> , 2019, 6, e00161.	0.4	1
87	Change in Alcohol Use and Association with Positive and Negative Emotions: Results from an Alcohol Treatment Study with Hepatitis C Patients. <i>Alcoholism Treatment Quarterly</i> , 2021, 39, 430-445.	0.8	1
88	Coordination, Cost, and Changing Epidemiology—Considerations in the Hepatitis C Care Cascade. <i>Hepatology Communications</i> , 2021, 5, 355-357.	4.3	1
89	Cirrhosis in hepatitis C virus-infected patients: a review for practitioners new to hepatitis C care. <i>Topics in Antiviral Medicine</i> , 2014, 22, 685-9.	0.1	1
90	IL28B Polymorphisms and Treatment of Hepatitis C. <i>Current Hepatitis Reports</i> , 2011, 10, 70-78.	0.3	0

#	ARTICLE	IF	CITATIONS
91	Approach to the Treatment-naïve Patient with HCV Genotype 1 Infection. Infectious Disease Clinics of North America, 2012, 26, 893-901.	5.1	0
92	IL28B: Implications for Clinical Practice. Current Hepatitis Reports, 2012, 11, 15-22.	0.3	0
93	Antiretroviral Effects on Host Lipoproteins Are Associated With Changes in Hepatitis C Virus (HCV) RNA Levels in Human Immunodeficiency Virus/HCV Coinfected Individuals. Open Forum Infectious Diseases, 2015, 2, ofv066.	0.9	0
94	Mechanisms of Ascites Development—Reply. JAMA - Journal of the American Medical Association, 2016, 316, 1829.	7.4	0
95	State of the State in Gastroenterology. North Carolina Medical Journal, 2016, 77, 176-179.	0.2	0
96	Hepatocellular Carcinoma Risk After Hepatitis C Cure. Current Treatment Options in Infectious Diseases, 2018, 10, 330-336.	1.9	0
97	HCV Exposure in the Health Care Arena. Is there a Role for Post-exposure Prophylaxis?. Current Hepatology Reports, 2019, 18, 222-227.	0.9	0
98	Is Magnetic Resonance Cholangiopancreatography Worth a Thousand Words in Determining Prognoses of Patients With Primary Sclerosing Cholangitis?. Clinical Gastroenterology and Hepatology, 2019, 17, 2654-2656.	4.4	0
99	What Clues Can We Use From Primary Sclerosing Cholangitis With Inflammatory Bowel Disease Phenotypes?. Clinical Gastroenterology and Hepatology, 2020, 18, 2173-2175.	4.4	0
100	Adaptive Challenges and Family Support: Patient Self-Management during Treatment for Chronic Hepatitis C. Nursing Science Quarterly, 2021, 34, 405-412.	0.8	0
101	Care After Cure: Long-term Follow-up in Hepatitis C. Current Hepatology Reports, 0, , 1.	0.9	0